2023
DOI: 10.3748/wjg.v29.i12.1863
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive review on endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 76 publications
0
7
0
Order By: Relevance
“…In PDAC, precision medicine is rapidly evolving, and in the era of next-generation sequencing (NGS), in which a relatively limited amount of tissue sample can be successfully analyzed for the detection of genetic alterations, EUS TA plays a major role. Such actionable molecular changes can be seen in about one-fourth of PDAC which can be targeted with precision medicine [ 129 ]. The detection of actionable molecular alterations has led to the development of various drugs acting on one or multiple molecular pathways, like the KRAS and DNA mismatch repair (MMR) pathway, and studies have shown better overall survival when patients are treated with matched therapy ( n = 143; 2.58 years vs. 1.51 years; hazard ratio (HR) of 0.42 (95%CI: 0.26–0.68), p < 0.001) [ 130 ].…”
Section: Recent Advancement In Eus Ta In Pancreatic Carcinomamentioning
confidence: 99%
“…In PDAC, precision medicine is rapidly evolving, and in the era of next-generation sequencing (NGS), in which a relatively limited amount of tissue sample can be successfully analyzed for the detection of genetic alterations, EUS TA plays a major role. Such actionable molecular changes can be seen in about one-fourth of PDAC which can be targeted with precision medicine [ 129 ]. The detection of actionable molecular alterations has led to the development of various drugs acting on one or multiple molecular pathways, like the KRAS and DNA mismatch repair (MMR) pathway, and studies have shown better overall survival when patients are treated with matched therapy ( n = 143; 2.58 years vs. 1.51 years; hazard ratio (HR) of 0.42 (95%CI: 0.26–0.68), p < 0.001) [ 130 ].…”
Section: Recent Advancement In Eus Ta In Pancreatic Carcinomamentioning
confidence: 99%
“…Endoscopic ultrasound-guided fine-needle tissue acquisition (EUS-TA) is recommended for the pathological diagnosis of mass lesions in the pancreas and used for the pathological diagnosis of PACC ( 68–70 ). EUS-TA is generally successful in obtaining tissue for diagnosis, and the incidence of adverse events is low in patients with pancreatic tumours ( 71 , 72 ). Because genetic analysis using histological specimens is needed in patients with unresectable pancreatic cancer, including PACC, large-gauge biopsy needles should be used, and multiple biopsy specimens should be obtained ( 73–77 ).…”
Section: Epidemiology Clinical Features Diagnosis Molecular Features ...mentioning
confidence: 99%
“…6,7 Endoscopic ultrasound-guided tissue acquisition (EUS-TA) via fine-needle aspiration (FNA) or fine-needle biopsy (FNB) is the primary sampling method for diagnosing solid pancreatic lesions. [8][9][10][11] For patients with pancreatic cancer, the role of EUS-TA has expanded from pathological diagnosis to obtaining adequate samples for molecular testing before initiating targeted therapies. [12][13][14] The current National Comprehensive Cancer Network guidelines recommend the consideration of germline testing, gene profiling, and mismatch repair/microsatellite instability testing for metastatic pancreatic ductal cancer.…”
Section: Introductionmentioning
confidence: 99%